Seeking Alpha

Keryx Biopharmaceuticals (KERX) +45.4% premarket on news its Zerenex experimental kidney disease...

Keryx Biopharmaceuticals (KERX) +45.4% premarket on news its Zerenex experimental kidney disease drug had met its late-stage trial goal of reducing phosphate levels in blood. KERX expects to submit a new drug application with the FDA and a marketing authorization application with the EMA for Zerenex in Q2.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs